Head of Investor Relations
Axon Enterprise, Inc. (AXON)Equibles does not estimate personal net worth.
Get an email with a short summary when Insight Molecular Diagnostics Inc. publishes a filing, an earnings call transcript or a press release.
Get IMDX alertsAndrea James is recorded as CFO at Insight Molecular Diagnostics Inc. (IMDX) and Head of Investor Relations at Axon Enterprise, Inc. (AXON). The newest filing on record that lists Andrea James as CFO at Insight Molecular Diagnostics Inc. (IMDX) is dated April 30, 2026. Insight Molecular Diagnostics Inc. reported in an 8-K filed June 17, 2024 that Andrea James was appointed Chief Financial Officer, effective June 17, 2024. The proxy statement of Insight Molecular Diagnostics Inc. reports total compensation of $1,679,126 for Andrea James in fiscal 2025, including a base salary of $367,355. Disclosed compensation is on record for 3 fiscal years. Andrea James has spoken on 9 earnings calls across 2 companies, most recently for Insight Molecular Diagnostics Inc. on May 13, 2026. Those appearances were for Insight Molecular Diagnostics Inc. (IMDX) and Axon Enterprise, Inc. (AXON). Insight Molecular Diagnostics Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Axon Enterprise, Inc. is classified in the Aerospace & Defense industry within the Industrials sector. Other leadership on record at Insight Molecular Diagnostics Inc. includes Joshua Riggs (CEO and Board Member), Ronald Andrews (CEO), Andrew Arno (Chairman and Board Member) and 7 others.
“On June 17, 2024, the Board of Directors (the "Board") of Oncocyte Corporation (the "Company") appointed Andrea James to serve as the Company's Chief Financial Officer, effective June 17, 2024.”
“Our first quarter results are in line with what we told you they would be and our preliminary release of our cash balance and revenue, which we made on April 14.”
“Okay, so since you've known us, this company has done one highly focused thing, and that is invest in product development for a kitted kidney transplant assay. And this year, we were preparing to do two focused things.”
“And I also just want to do a quick shout out to Gabby Woody, who's emceeing this call and who Zoom decided to malfunction right before we went live. So anyway, you've got our financial tables in the shareholder letter and in the 10 Qs.”
“Before I briefly give financial highlights, I want to warmly invite our analysts and investors to our key opinion leader webinar scheduled for Friday, August 15, and that will feature Vanderbilt University's Doctor Langone, who is leading the efforts for our ongoing clinical trial, as Josh mentioned.”
“Just a few financial highlights this quarter. First, farmer services revenue of $2.1 million exceeded our expectations, particularly with a large order that came in late in the quarter that we processed quickly and efficiently.”
Start not stated–present
Last confirmed April 30, 2026
Diagnostics & Research · Healthcare
CFO
Aerospace & Defense · Industrials
Head of Investor Relations
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Insight Molecular Diagnostics Inc. (IMDX) | Chief Financial Officer | $367,355 | $1,679,126 |
| 2024 | Insight Molecular Diagnostics Inc. (IMDX) | Chief Financial Officer | $175,165 | $758,863 |
| 2023 | Insight Molecular Diagnostics Inc. (IMDX) | Chief Financial Officer | — | — |
